Keywords: pharma, cut, aids, drug, prices, china, bristol-myers
Pharma "to cut AIDS drug prices in China"
Article | 04 December 2001
Bristol-Myers Squibb and GlaxoSmithKline are currently reported to bereadying significant price reductions on their HIV/AIDS drug treatments in China, ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Italy's pharma market slump set to continue, warns GlobalData
